What is Halozyme Therapeutics's change in AP?

Halozyme Therapeutics (HALO) reported change in AP of -$24.92M in Q1 2026.

How has Halozyme Therapeutics's change in AP changed year-over-year?

Halozyme Therapeutics's change in AP decreased by 370.3% year-over-year, from $9.22M to -$24.92M.

What is the long-term trend for Halozyme Therapeutics's change in AP?

Over 2 years (2021 to 2025), Halozyme Therapeutics's change in AP has grown at a 130.7% compound annual growth rate (CAGR), from $1.17M to $6.21M.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Halozyme Therapeutics HALO Change in AP

Change in AP at other companies

West Pharmaceutical ServicesWST

$4.48M+517%

BridgeBio PharmaBBIO

-$7.17M-141%

Arrowhead ResearchARWR

$15.26M+397%

AptarGroupATR

$36.42M+9.3%

AbbVieABBV

-$1.59B-129%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's change in AP?: Halozyme Therapeutics (HALO) reported change in AP of -$24.92M in Q1 2026.
How has Halozyme Therapeutics's change in AP changed year-over-year?: Halozyme Therapeutics's change in AP decreased by 370.3% year-over-year, from $9.22M to -$24.92M.
What is the long-term trend for Halozyme Therapeutics's change in AP?: Over 2 years (2021 to 2025), Halozyme Therapeutics's change in AP has grown at a 130.7% compound annual growth rate (CAGR), from $1.17M to $6.21M.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.